Severe hypoglycemia was associated with increased risk for adverse clinical outcomes in type 2 diabetes
- Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes. Aron, David C.; Pogach, Leonard M. // ACP Journal Club;11/16/2010, Vol. 153 Issue 5, p8
The article discusses author's views on the impact of intensive glucose control on the patients with type 2 diabetes suffering from cardiovascular (CV) disorders. A study called Action to Control Cardiovascular Risk in Diabetes (ACCORD) reveals that advanced microvascular disease cannot be...
- Efficacy of secondline therapies added to metformin in T2D. // Diabetes Digest;2012, Vol. 11 Issue 3, p143
The article discusses a study conducted by S. C. Liu, Y. K. Tu, M. N. Chien and colleagues comparing the efficacy of second-line antidiabetes drugs in people with T2D taking metformin.
- 2011 - Adding a panel manager to EMR reminders improved some preventive care processes. Lim, Lionel S. // ACP Journal Club;1/17/2012, Vol. 156 Issue 1, p11
No abstract available.
- High-dose statin therapy significantly affects T2D glycaemic control. // Diabetes Digest;2012, Vol. 11 Issue 3, p140
The article presents a brief summary of the CORALL study by S. Simsek and colleagues, which compares the lipid-lowering effects of two statins, including rosuvastatin and atorvastatin in people with dislipidaemia and type 2 diabetes.
- 2012 - Gastric bypass or biliopancreatic diversion increases remission from type 2 diabetes in obese adults. Pokala, Suma // ACP Journal Club;7/17/2012, Vol. 157 Issue 2, p1
The article discusses effects of gastric bypass or biliopancreatic diversion medical therapy in improving diabetes conditions of patients. It reports maintenance of normal blood glucose level in clinical trial group of patients that underwent gastric bypass or biliopancreatic diversion therapy....
- For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk. Bellary, Srikanth // Evidence Based Medicine;Apr2011, Vol. 16 Issue 2, p39
A review is presented of the article "Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain and Hypoglycemia in Type 2 Diabetes" by O. J. Phung, J. M. Scholle, M. Talwar et al., which appeared in a 2010 issue of the "Journal of the American Medical...
- Liuwei Dihuang Pills (å…å‘³åœ°é»„ä¸¸) enhance the effect of Western medicine in treating type 2 diabetes: A meta-analysis of randomized controlled trials. Pu, Run; Geng, Xiang-nan; Yu, Fei; Liang, Hui-gang; Shi, Lu-wen // Chinese Journal of Integrative Medicine;Oct2013, Vol. 19 Issue 10, p783
Objective: To perform meta-analyses evaluating the efficacy of adding Liuwei Dihuang Pills (å…å‘³åœ°é»„ä¸¸, LDP) to Western medicine in improving treatment outcomes for type 2 diabetes. Methods: Medline, PubMed, Cochrane Library, and Chinese databases, including the Chinese...
- Effect of royal jelly intake on serum glucose, HbA1c, and total antioxidant capacity (TAC) in type 2 diabetic patients: a randomized, double blind clinical trial study. Khoshpey, Basmeh; Shidfar, Farzad; Jazayeri, Shima; Malek, Mojtaba; Fatemeh Hosseini, Agha // Razi Journal of Medical Sciences;Jan2013, Vol. 19 Issue 103, p33
Background: Type 2 diabetes melitus (DM) is highly prevalent worldwide. Evidence supports a role for royal jelly in reduction of serum glucose and lipids. The purpose of this study was to determine the effects of royal jelly intake on serum glucose, HbA1c, and Total Antioxidant Capacity (TAC) in...
- FFAR1 found to be a viable therapeutic target in the treatment of T2D. // Diabetes Digest;2012, Vol. 11 Issue 3, p144
The article discusses research being done on free fatty acid receptor 1 (FFAR1) as a viable target for treatment of type 2 diabetes (T2D). It references the study "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial,"...